2354321-33-6
2354321-33-6
Chemical Structure
NMD670
- CAS No.: 2354321-33-6
- Formula:C12H10BrNO4
- Molecular Weight:312.12
InChIKey: XKXLEZCOELWNMB-ZETCQYMHSA-N
SMILES: OC([C@H](C)OC1=CC=C(Br)C=C1C2=NOC=C2)=O
Biological Activity: NMD670 is an orally active inhibitor of skeletal muscle specific chloride channel ClC-1 with an EC50 of 1.6 μM. NMD670 enhances neuromuscular transmission and improves muscle contraction and strength. NMD670 can be used in the study of muscle weakness and muscle fatigue[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NMD670 | 99.60% | NMD670 is an orally active inhibitor of skeletal muscle specific chloride channel ClC-1 with an EC50 of 1.6 μM. NMD670 enhances neuromuscular transmission and improves muscle contraction and strength. NMD670 can be used in the study of muscle weakness and muscle fatigue. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Skov M, et al. The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis. Sci Transl Med. 2024 Mar 20;16(739):eadk9109. [Content Brief]
- [2]. Chin E, et al. Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial. Clin Pharmacol Ther. 2024 Dec 9. [Content Brief]
Keywords
